Biologically active crystalline forms of tripentadecanoin
A metastable crystalline form of tripentadecanoin with specific PXRD peaks addresses the lack of bioactivity and bioavailability in existing polymorphs, offering enhanced therapeutic efficacy for neurodegenerative diseases and other conditions.
Patent Information
- Application Number
- PCT/US2026/024752
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-04-22
- Publication Date
- 2026-11-12
AI Technical Summary
Existing triglycerides like tripentadecanoin tend to crystallize as polymorphs, lacking enhanced bioactivity and bioavailability, necessitating the development of specific polymorphs with improved properties.
A metastable crystalline form of tripentadecanoin with distinct Powder X-ray Diffraction (PXRD) peaks at 19.3°, 22.8°, 23.7°, and 24.6° is developed, along with a pharmaceutical composition incorporating this form and pharmaceutically acceptable excipients for enhanced bioactivity and bioavailability.
The metastable crystalline form of tripentadecanoin exhibits improved bioactivity and bioavailability, suitable for treating neurodegenerative conditions and other diseases, and is stable in pharmaceutical compositions.
Smart Images

Figure US2026024752_12112026_PF_FP_ABST
Abstract
Description
[0001] Docket No. SUNH-002-W01
[0002] BIOLOGICALLY ACTIVE CRYSTALLINE FORMS OF TRIPENTADECANOIN
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to US Provisional Patent Application Serial No. 63 / 803,031, filed on May 9, 2025. The content of the prior application is hereby incorporated by reference in its entirety.
[0004] BACKGROUND
[0005] Ophioglossum thermale is a medicinal herb used in traditional Chinese medicine as a rescuing treatment for snake bite toxicity and occasionally for conditions of neuronal atrophy. Tripentadecanoin, a rare triglyceride, has been reported to be present in Ophioglossum extracts.
[0006] Triglycerides such as tripentadecanoin are characterized by a tendency to crystallize as polymorphs, meaning that they are able to form different crystalline structures depending on several factors that include chemical composition, presence of impurities, thermal history, measurement conditions (e.g., heating or cooling rate in dynamic conditions), and the dwell time under isothermal conditions.
[0007] The need exists to develop specific polymorphs of tripentadecanoin that have enhanced bioactivity and / or bioavailability
[0008] SUMMARY
[0009] To meet this need, a metastable crystalline form of tripentadecanoin is provided that has a Powder X-ray Diffraction (PXRD) 2 theta peak of about 19.3°. The metastable crystalline form of tripentadecanoin can also have one or more PXRD 2 theta peaks of about 22.8°, 23.7°, and 24.6°.
[0010] Also provided is a pharmaceutical composition that includes the metastable crystalline form of tripentadecanoin and one or more pharmaceutically acceptable excipients.
[0011] Further disclosed is a method for treating a neurodegenerative condition by administering the pharmaceutical composition that includes the metastable crystalline form of tripentadecanoin.
[0012] The details of one or more embodiments of the invention are set forth in the drawings and description below. Other features, objects, and advantages of the invention will be apparent from the description, from the drawings, and from the claims. All references cited herein are hereby incorporated by reference in their entirety.
[0013] 1
[0014] 4928-6572-5851 , v. 1Docket No. SUNH-002-W01
[0015] BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Fig. 1 shows plots for Differential Scanning Calorimetry (DSC) analysis of SBC003 under heating / cooling cycles
[0017] Fig. 2 is a Powder X-ray Diffraction (PXRD) plot of crystalline Form 1 of SBC003, Fig. 3 shows the Thermo gravimetric analysis (TGA) of crystalline Form 1 of SBC003, Fig. 4 shows the DSC analysis of crystalline Form 1 of SBC003,
[0018] Fig. 5 shows the1H Nuclear Magnetic Resonance (NMR) peaks for crystalline Form 1 of SBC003,
[0019] Fig. 6 is a polarized light microscopy (PLM) image of crystalline Form 1 of SBC003, Fig. 7 is a PXRD plot of crystalline Form 2 of SBC003,
[0020] Fig. 8 shows the TGA of crystalline Form 2 of SBC003,
[0021] Fig. 9 shows the DSC analysis of crystalline Form 2 of SBC003,
[0022] Fig. 10 shows the1H NMR peaks for crystalline Form 2 of SBC003,
[0023] Fig. 11 is a PLM image of crystalline Form 2 of SBC003,
[0024] Fig. 12 is a PXRD plot of crystalline Form 3 of SBC003,
[0025] Fig. 13 shows the TGA of crystalline Form 3 of SBC003,
[0026] Fig. 14 shows the DSC analysis of crystalline Form 3 of SBC003,
[0027] Fig. 15 shows the1H NMR peaks for crystalline Form 3 of SBC003,
[0028] Fig. 16 is a PLM image of crystalline Form 3 of SBC003,
[0029] Fig. 17 shows PXRD plots of crystalline Form 1 (bottom curve), Form 2 (middle curve), and Form 3 (top curve).
[0030] DETAILED DESCRIPTION
[0031] A metastable crystalline form of tripentadecanoin has a Powder X-ray Diffraction (PXRD) 2 theta peak of about 19.3°.
[0032] A metastable crystalline form of tripentadecanoin has a Powder X-ray Diffraction (PXRD) 2 theta peak of about 22.87°.
[0033] A metastable crystalline form of tripentadecanoin has a Powder X-ray Diffraction (PXRD) 2 theta peak of about 23.7°.
[0034] A metastable crystalline form of tripentadecanoin has a Powder X-ray Diffraction (PXRD) 2 theta peak of about 24.6°.
[0035] A metastable crystalline form of tripentadecanoin has a Powder X-ray Diffraction (PXRD) 2 theta peak of about 19.3° and one or more PXRD 2 theta peaks of about 22.87°, 23.7°,
[0036] 2
[0037] 4928-6572-5851 , v. 1Docket No. SUNH-002-W01
[0038] and 24.6°. Preferably, the metastable crystalline form of tripentadecanoin has PXRD 2 theta peaks of about 19.3°, 22.87°, 23.7°, and 24.6°.
[0039] Also encompassed by the invention is a pharmaceutical composition that includes the metastable crystalline form of tripentadecanoin described above and one or more pharmaceutically acceptable excipients. The excipients can be, but are not limited to, Diluents / Fillers: Microcrystalline cellulose (MCC, e.g., Avicel®), Lactose (anhydrous or monohydrate), Mannitol, Dibasic calcium phosphate (e.g., Di-Tab®), Starch (com, potato, pregelatinized); Binders (for tablet cohesion): Hydroxypropyl methylcellulose (HPMC), Polyvinylpyrrolidone (PVP, e.g., Kollidon®), Starch paste, Methylcellulose, Ethylcellulose (for controlled release); Disintegrants (for rapid breakdown): Croscarmellose sodium (e.g., Ac-Di-Sol®), Sodium starch glycolate (e.g., Explotab®), Crospovidone (e.g., Kollidon® CL), Low-substituted hydroxypropyl cellulose (L-HPC); Lubricants & Anti-adherents (for processing): Magnesium stearate, Stearic acid, Sodium stearyl fumarate, Talc, Glyceryl behenate (e.g., Compritol®); Glidants (for powder flow improvement), Colloidal silicon dioxide (e.g., Aerosil®), Talc; Surf actants / Wetting Agents (for solubility enhancement), Sodium lauryl sulfate (SLS), Polysorbates (Tween® 20, 80), Sorbitan esters (Span®), Polyethylene glycol (PEG) derivatives; Stabilizers (for metastable form preservation): Antioxidants (e.g., BHA, BHT, ascorbic acid), Chelating agents (e.g., EDTA), pH modifiers (buffers like citrate, phosphate); Coating Agents (for tablets / capsules): Hypromellose (HPMC), Polyethylene glycol (PEG)-based coatings, Enteric polymers (e.g., Eudragit® L / S), Shellac; Solubility Enhancers: Cyclodextrins (e.g., Sulfobutylether-P-cyclodextrin), Lipid-based carriers (e.g., Gelucire®); and Preservatives (for liquid / semisolid forms), Parabens (methyl, propylparaben), Benzyl alcohol, Phenol.
[0040] The pharmaceutical compositions of the invention can be, for example, in the form of a soft gelatin (soft gel) capsule. A soft gel capsule provides a patient-friendly dosage form for peroral administration of nonpalatable and / or oily liquids, such as tripentadecanoin. The proper choice of vehicle may promote rapid dispersion of capsule contents and drug dissolution. A higher degree of reproducibility is achieved during the manufacture of soft gelatin capsules than is possible with powders or granules used for the manufacture of tablets or hard gelatin capsules since the liquid fill is metered into individual capsules via positive displacement pump. Soft gel capsules can be particularly advantageous for low dose drugs that are lipid-soluble because it can allow greater uniformity of content between dosage units than conventional tablet dosage forms. Lastly, soft gel capsules are hermetically sealed as a natural consequence of the manufacturing
[0041] 3
[0042] 4928-6572-5851 , v. 1Docket No. SUNH-002-W01
[0043] process. Thus, this dosage form is uniquely suited for liquids and volatile drugs. Many drugs subject to atmospheric oxidation may also be formulated satisfactorily in this dosage form. In certain embodiments of the pharmaceutical composition, the pharmaceutically acceptable excipients stabilize the metastable crystalline form of tripentadecanoin.
[0044] Further disclosed is a method for treating a neurodegenerative condition by administering the pharmaceutical composition to a subject suffering from a neurodegenerative condition. The neurodegenerative condition can be, but is not limited to, Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Amyotrophic lateral sclerosis (ALS), dementia, Dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), Creutzfeldt- Jakob disease, and brain atrophy.
[0045] Also within the scope of this disclosure is use of the metastable crystalline form of tripentadecanoin for the manufacture of a medicament for the treatment and / or prevention of neurodegenerative diseases, retinal or optic nerve degenerative diseases, demyelinating diseases, neuromuscular disorders and muscular dystrophy, brain or spinal cord nerve injury, cranial nerve disorders, or seizures, amyloid deposit related diseases, chronic diseases selected from the group consisting of kidney diseases, diabetes and asthma, and for the use of anti-aging or life-span prolongation and improving brain function.
[0046] Neurodegenerative diseases include Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Amyotrophic lateral sclerosis (ALS), dementia, Dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), Creutzfeldt- Jakob disease, and brain atrophy.
[0047] Retinal and optic degenerative diseases include optical atrophy, Leber's hereditary optic neuropathy (LHON) , Dominant Optic Atrophy (DOA) and age-related macular degeneration, glaucoma and retinitis pigmentosa.
[0048] Demyelinating diseases include adrenoleukodystrophy, multiple sclerosis, optical neuritis, Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre syndrome, encephalitis caused by or related to Zika virus, cranial nerve palsy, neuromyelitis optica (NMO), acute disseminated encephalomyelitis, acute necrotizing hemorrhagic encephalitis, concentric sclerosis, diffuse sclerosis, metachromatic leukodystrophy, ball-like cell leukodystrophy, spongy degeneration of the central nervous system, Perry-plum disease, Alexander disease, radiation injury leukoencephalopathy, hypoxic leukoencephalopathy, periventricular leukomalacia disease, arteriosclerotic cortex under encephalopathy, progressive multifocal leukoencephalopathy, and central pontine myelinolysis syndrome.
[0049] 4
[0050] 4928-6572-5851 , v. 1Docket No. SUNH-002-W01
[0051] Neuromuscular disorders and muscular dsytrophy diseases include myasthenia gravis, Lambert-Eaton syndrome, Duchenne muscular dystrophy, Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, Charcot-Marie-Tooth disease (CMT).
[0052] Neurological injury related diseases or mixed neurological diseases include acute or chronic brain injury or spinal cord nerve injury, cranial nerve disorders and seizures.
[0053] Amyloid deposit related diseases include diabetes, cardiac amyloidosis, primary amyloidosis, familial amyloidosis, senile systemic amyloidosis (SSA), secondary amyloidosis, and hemodialysis-associated amyloidosis.
[0054] Chronic diseases include kidney diseases, diabetes, and asthma.
[0055] The metastable crystalline form of tripentadec anoin compound is typically administered to a patient in need thereof in a dosage from 1 mg / day to 1000 mg / day.
[0056] The metastable crystalline form of tripentadec anoin can be used as functional food or food supplement for human and / or animal, e.g., at a dosage of from 1 pg (microgram) / day to 50 mg / day.
[0057] The metastable crystalline form of tripentadec anoin can be contained in ophioglossum in an amount of 1 mg / day to 1000 mg / day. A pharmaceutical composition optionally contains ophioglossum, e.g., as functional food or food supplement for human and / or animal, preferably tripentadecanoin contained in ophioglossum in an amount of 1 pg (microgram) / day to 50 mg / day.
[0058] The metastable crystalline form of tripentadecanoin is also useful in the treatment, prevention and / or alleviation of symptoms of neurological complication(s) of a viral infection disease.
[0059] The viral infection disease is often caused by SARS-CoV-2, SARS- CoV-1, MERS, influenza virus, human immunodeficiency virus (HIV), varicella- zoster virus (VZV), herpes simplex virus (HSV), poliovirus, Epstein-Barr virus (EBV) cytomegalovirus (CMV), Japanese Encephalitis virus, Venezuelan Equine Encephalitis virus, California encephalitis virus or zika virus.
[0060] The neurological complication of a viral infection disease can be damage of the central nervous system, in particular of brainstem or the peripheral nervous system, with conditions such as difficulties in breathing and / or in heartbeat, muscle weakness, loss of taste and / or smell, limb pain, malaise, headache, seizures, perivascular encephalitis, interstitial encephalitis, neuronal cell loss, and / or axon degeneration.
[0061] 5
[0062] 4928-6572-5851 , v. 1Docket No. SUNH-002-W01
[0063] Preventing neurological complication(s) of a viral infection disease includes preventing an onset of neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease.
[0064] Preventing the neurological complication(s) of a viral infection disease includes preventing cardiorespiratory failure.
[0065] The metastable crystal form of tripentadecanoin upon administration to the subject can upregulate expression of neuroglobin, preferably in neuron cells, wherein upregulated expression of neuroglobin inhibits apoptosis of neuron cells.
[0066] Without further elaboration, it is believed that one skilled in the art can, based on the description above, utilize the present invention to its fullest extent. The specific example below is to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
[0067] Examples
[0068] Example 1 : Analytical Methods
[0069] Powder X-ray diffraction (PXRD)
[0070] A Bruker D8 Advance diffractometer was employed for these analyses, which uses a copper target K with a wavelength of 1.54Aa radiation, 40 kV and 40 mA operating conditions, 0-20 goniometer, nickel flake filtration, SSD160-2 detector. The instrument was calibrated with the standard (corundum) that comes with the instrument before use. Samples were tested at room temperature, and the sample to be tested is placed on a non-reflective plate. The detailed detection conditions are as follows, angle range: 3~4O°20, step size: O.O2°20, speed: 0.1 seconds / step.
[0071] Thermo gravimetric analysis (TGA)
[0072] TGA data was collected using a METTLER TOLEDO TGA2 with the instrument control and analysis STARe software. 1~ 10 mg of each sample was placed in an open aluminum crucible and the sample was raised from 30 °C to 350 °C at a temperature rise rate of 10 °C / min under 50 mL / min dry nitrogen.
[0073] Differential Scanning Calorimetry (DSC)
[0074] DSC data was collected using a METTLER TOLEDO DSC3 instrument with STARe software. 0.5-5 mg of each sample was placed in an aluminum crucible (capped and perforated), and the samples were raised from 30°C to 300°C at a heating rate of 10°C / min under 50 mL / min dry nitrogen.
[0075] 6
[0076] 4928-6572-5851 , v. 1Docket No. SUNH-002-W01
[0077] 2HNMR
[0078] Nuclear magnetic hydrogen spectroscopy (!H NMR) data was collected using a Bruker AVANCE III instrument. 400 MHz / Bruker AVANCE NEO 400 MHz, full frequency excitation, spectral width 20 ppm single pulse, 30° angle excitation scan 8 times, digital orthogonal detection, temperature control 298 K. The solvent was DMSO-d6.
[0079] Example 2: DCS analysis of synthetic SBC003
[0080] The sample of SBC003 (synthetic tripentadecanoin) was heated in two cycles to 75°C in a pierced aluminum crucible and cooled down to room temperature afterwards. The temperature ramps were 10 K / min. The results are shown in Fig. 1. At the onset temperature of 55.9°C (peak 58.7°C) an endothermic event (melting) was observed. See Fig. 1, topmost plot. After the first cool-down process, an exothermic event (recrystallization) was observed at 32.3°C. See Fig. 1, second plot from the top. The second heating curve (Fig. 1, third plot) showed an endothermic event (onset: 39.2°C) followed by an exothermic process (peak: 42.5°C) which was accompanied by a melting process (onset: 50.3°C) . Within the second cool-down process an exothermic process (recrystallization) was observed at 32.2°C. See the bottom plot in Fig.l. The second heat curve indicates the presence of a metastable second crystalline phase which crystallizes back into a more stable form.
[0081] Example 3: Powder X-ray Diffraction
[0082] To confirm the above finding, powder X-ray diffraction analysis (PXRD) was carried out on samples of synthetic tripentadecanoin (designated SBC003). The main 29 peaks are shown in Table 1 below.
[0083] Table 1. Powder X-ray Diffraction Analysis
[0084] Synthetic tripentadecanoin
[0085] Published tripentadecanoin
[0086] (SBC300)
[0087] Peak 29 / intensity Peak 29 / intensity
[0088] 9.940 / 29269.9 19.304 / 29.7%
[0089] 10.670 / 306848.6 22.741 / 27.0%
[0090] 12.630 / 400229.7 23.626 / 7.6 %
[0091]
[0092] 13.305 / 113265.4 24.504 / 14.0 %
[0093] Published PXRD data for tripentadecanoin shows major peaks between 10° and 13° 29. See Helmholdt et al., Acta Cryst. (2002). B58, 134-139. By contrast, SBC300 had major peaks between 19° and 24.6° 29.
[0094] 7
[0095] 4928-6572-5851 , v. 1Docket No. SUNH-002-W01
[0096] Example 4: Polymorph Generation
[0097] Methanol (0.5 mL) was added to 20 mg of SBC003 and the resulting suspension was stirred at 5°C for 4 days and centrifuged to obtain crystalline Form 1.
[0098] 200 mg of SBC003 was added to a 20.0 mL vial, followed by 0.4 mL of mixed solvent (chloroform / n-hexane = 1:1). The mixture was ultrasonically dissolved, filtered, and the filtrate was placed at room temperature open to volatilize to obtain crystalline Form 2.
[0099] 200 mg of SBC003 was added to a 20.0 mL vial, which was then placed in a blast drying oven at a temperature of 80 °C until the sample melted. The vial was removed from the oven and placed in dry ice to cool quickly to obtain crystalline Form 3.
[0100] Example 5: Characterization of Crystalline Forms
[0101] Each crystalline form of tripentadecanoin was characterized by PXRD, TGA, DCA, and!H NMR according to the procedures set forth above in Example 1. Samples were also examined by polarized light microscopy following standard procedures. The results are shown in Figs. 2-6 (crystalline Form 1), Figs. 7-11 (crystalline Form 2), and Figs. 12-16 (crystalline Form 3). A summary of the results is shown in Table 2 below.
[0102] Table 2. Crystalline polymorph summary
[0103] DSC ’H NMR
[0104] Preparation TGA weight
[0105] Polymorph endothermic solvent signal Result scale loss(%)(120°C)
[0106] (°C, onset) (solvent: API)
[0107] No significant
[0108] Form 1 N / A 1.01 56.00 Anhydrous solvent residue
[0109] No significant
[0110] Form 2 200 mg 0.87 55.99 Anhydrous solvent residue 38.83, 41.66*, No significant
[0111] Form 3 100 mg 0.73 Anhydrous
[0112]
[0113] 51.39 solvent residue *Exothermic peak (onset).
[0114] The results clearly showed that at least three polymorphic crystalline forms of tripentadecanoin could be produced from the synthesized starting material.
[0115] Example 6: Solubility of Crystalline Forms
[0116] The three crystalline forms described above were tested in an equilibrium solubility assay to assess their suitability as drugs for oral administration. Samples of each crystalline form were stirred in each of 4 test solutions, namely, H2O, fasted state simulated gastric fluid (FaSSGF), fed state simulated intestinal fluid (FeSSIF), and fasted state simulated intestinal fluid (FaSSIF) for 24 hours at 37°C. The results are shown below in Table 3.
[0117] 8
[0118] 4928-6572-5851 , v. 1Docket No. SUNH-002-W01
[0119] Table 3. Solubility of Crystalline forms
[0120] Crystalline form System Equilibrium solubility (pg / mL)
[0121] H2O <1
[0122] FaSSGFa(pH 1.6) <1
[0123] Form 1
[0124] FeSSIFb(pH 5.0) 251
[0125] FaSSIFc(pH 6.5) 34
[0126] H2O <1
[0127] FaSSGF (pH 1.6) <1
[0128] Form 2
[0129] FeSSIF (pH 5.0) 984
[0130] FaSSIF (pH 6.5) 299
[0131] H2O <1
[0132] FaSSGF (pH 1.6) <1
[0133] Form 3
[0134] FeSSIF (pH 5.0) 231
[0135]
[0136] FaSSIF (pH 6.5) 265
[0137] aFasted State Simulated Gastric Fluid
[0138] bFed State Simulated Intestinal Fluid
[0139] cFasted State Simulated Intestinal Fluid
[0140] All of the crystalline forms were essentially insoluble in H2O and FaSSGF. All three forms were soluble in FaSSIF and FeSSIF, with Form having highest solubility.
[0141] The solid material that did not dissolve during the course of the assay was examined to determine the stability of the crystalline forms. Notably, crystalline Form 1 was stable, as the undissolved material retained the same crystalline properties as before the assay. The crystalline structure of the undissolved material of Form 2 and Form 3 was not stable over the course of the assay. The undissolved solids from Crystalline Form 2 had the characteristics of Crystalline Form 1 or a mixture of Forms 1 and 2. The undissolved solids from Crystalline Form 3 had the characteristics of Crystalline Form 1 or showed an amorphous structure in FeSSIF.
[0142] Example 7: Biological activity
[0143] Biological assays also confirmed the difference between SBC300 containing the metastable crystalline form and samples lacking it. More specifically, SBC003 has biological effects if it was formulated in a rapid and non-heat generating way. The biological activity was lost if SBC300 was formulated using a process that included repeated heating or cooling steps.
[0144] OTHER EMBODIMENTS
[0145] All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.
[0146] 9
[0147] 4928-6572-5851 , v. 1Docket No. SUNH-002-W01
[0148] From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the scope of the following claims.
[0149] 4928-6572-5851 , v. 1
Claims
Docket No. SUNH-002-W01CLAIMSWhat is claimed is:
1. A metastable crystalline form of tripentadecanoin, having a Powder X-ray Diffraction (PXRD) 2 theta peak of about 19.3°.
2. The metastable crystalline form of tripentadecanoin of claim 1, having a further PXRD 2 theta peak of about 22.8°.
3. The metastable crystalline form of tripentadecanoin of claim 1 or claim 2, having a further PXRD 2 theta peak of about 23.7°.
4. The metastable crystalline form of tripentadecanoin of any of claims 1 to 3, having a further PXRD 2 theta peak of about 24.6°.
5. A pharmaceutical composition comprising the metastable crystalline form of tripentadecanoin of any of the preceding claims and one or more pharmaceutically acceptable excipients.
6. The pharmaceutical composition of claim 5, wherein the one or more pharmaceutically acceptable excipients stabilize the metastable crystalline form of tripentadecanoin.
7. A method for treating a neurodegenerative condition, the method comprising administering the pharmaceutical composition of claim 5 or 6 to a subject in need thereof.
8. The method of claim 7, wherein the neurodegenerative condition is Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis (ALS), dementia, Dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), Creutzfeldt-Jakob disease, or brain atrophy.114928-6572-5851 , v. 1
